3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
4
Unknown
3
Recruiting
2
Withdrawn
1
Terminated
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Mesothelioma, Malignant
1
Leukemia, Myeloid, Acute
1
Head and Neck Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Anus Neoplasms
1
Interventions
Etoposide
6
Radiotherapy
4
Cisplatin
3
Docetaxel
2
Carboplatin
2
venetoclax
1
trametinib
1
toripalimab
1
tislelizumab
1
talazoparib
1
sacituzumab govitecan
1
rovalpituzumab tesirine
1
regorafenib
1
poly ICLC
1
pembrolizumab
1
olaparib
1
obatoclax
1
nintedanib
1
fludarabine phosphate
1
etoposide phosphate
1
enoxaparin sodium
1
durvalumab
1
alpha-Tocopherol
1
Vitamin E
1
Topotecan
1
Tomography, Optical Coherence
1
Thymalfasin
1
Taxes
1
Polymerase Chain Reaction
1
Peripheral Blood Stem Cell Transplantation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Small Cell Lung Carcinoma
×
tislelizumab
×
Clear all
NCT05582031
2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2
Withdrawn